{
    "PMC5564609_3": [
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Delayed gastric emptying",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83",
                "statistical test": "Fisher exact test"
            },
            "measures": "[count (ERAS), count (Conventional), P]",
            "outcomes": "[15, 32, 0.02]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Bleeding",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83",
                "statistical test": "Fisher exact test"
            },
            "measures": "[count (ERAS), count (Conventional), P]",
            "outcomes": "[6, 4, 0.5]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Pancreatic fistula",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83",
                "statistical test": "Fisher exact test"
            },
            "measures": "[count (ERAS), count (Conventional), P]",
            "outcomes": "[39, 36, 0.52]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Grade A Pancreatic fistula",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83"
            },
            "measures": "[count (ERAS), count (Conventional)]",
            "outcomes": "[8, 6]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Grade B Pancreatic fistula",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83"
            },
            "measures": "[count (ERAS), count (Conventional)]",
            "outcomes": "[10, 6]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Grade C Pancreatic fistula",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83"
            },
            "measures": "[count (ERAS), count (Conventional)]",
            "outcomes": "[21, 24]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Biliary fistula",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83",
                "statistical test": "Fisher exact test"
            },
            "measures": "[count (ERAS), count (Conventional), P]",
            "outcomes": "[2, 0, 0.47]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Wound infection",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83",
                "statistical test": "Fisher exact test"
            },
            "measures": "[count (ERAS), count (Conventional), P]",
            "outcomes": "[5, 3, 0.66]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Pulmonary complication",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83",
                "statistical test": "Fisher exact test"
            },
            "measures": "[count (ERAS), count (Conventional), P]",
            "outcomes": "[2, 4, 0.1]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Skin orifice infection",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83",
                "statistical test": "Fisher exact test"
            },
            "measures": "[count (ERAS), count (Conventional), P]",
            "outcomes": "[1, 6, 0.012]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Abdominal abscess",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83"
            },
            "measures": "[count (ERAS), count (Conventional)]",
            "outcomes": "[0, 0]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Pancreatitis",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83",
                "statistical test": "Fisher exact test"
            },
            "measures": "[count (ERAS), count (Conventional), P]",
            "outcomes": "[2, 1, 1]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Sepsis",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83",
                "statistical test": "Fisher exact test"
            },
            "measures": "[count (ERAS), count (Conventional), P]",
            "outcomes": "[1, 0, 1]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Re-laparotomy",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83",
                "statistical test": "Fisher exact test"
            },
            "measures": "[count (ERAS), count (Conventional), P]",
            "outcomes": "[3, 1, 0.6]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Mortality",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83"
            },
            "measures": "[count (ERAS), count (Conventional)]",
            "outcomes": "[0, 0]"
        },
        {
            "subject": {
                "analysis": "Post-operative complications and mortalities",
                "group": "ERAS",
                "comparison group": "Conventional",
                "parameter": "Readmission (in 30 days)",
                "sample size (ERAS)": "76",
                "sample size (Conventional)": "83",
                "statistical test": "Fisher exact test"
            },
            "measures": "[count (ERAS), count (Conventional), P]",
            "outcomes": "[1, 1, 1]"
        }
    ],
    "PMC3798558_1": [
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "Age <40",
                "n": "185",
                "percentage": "5.41%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "5.12%",
                "statistical test": "chi-square test",
                "P-value": "0.999"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "Age \u226540 but <50",
                "n": "185",
                "percentage": "10.27%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "10.03%",
                "statistical test": "chi-square test",
                "P-value": "0.999"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "Age \u226550 but <60",
                "n": "185",
                "percentage": "32.43%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "32.70%",
                "statistical test": "chi-square test",
                "P-value": "0.999"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "Age \u226560 but <70",
                "n": "185",
                "percentage": "32.43%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "33.04%",
                "statistical test": "chi-square test",
                "P-value": "0.999"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "Age \u226570",
                "n": "185",
                "percentage": "19.46%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "19.11%",
                "statistical test": "chi-square test",
                "P-value": "0.999"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "Male",
                "n": "185",
                "percentage": "68.65%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "74.88%",
                "statistical test": "chi-square test",
                "P-value": "0.068"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "Female",
                "n": "185",
                "percentage": "31.35%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "25.12%",
                "statistical test": "chi-square test",
                "P-value": "0.068"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "Current BMI <18.5",
                "n": "185",
                "percentage": "8.11%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "4.16%",
                "statistical test": "chi-square test",
                "P-value": "0.021"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "Current BMI \u226518.5 but <22.5",
                "n": "185",
                "percentage": "45.11%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "37.88%",
                "statistical test": "chi-square test",
                "P-value": "0.021"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "Current BMI \u226522.5 but <25",
                "n": "185",
                "percentage": "25.41%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "32.63%",
                "statistical test": "chi-square test",
                "P-value": "0.021"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "Current BMI \u226525 but <27.5",
                "n": "185",
                "percentage": "13.51%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "16.72%",
                "statistical test": "chi-square test",
                "P-value": "0.021"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "Current BMI \u226527.5",
                "n": "185",
                "percentage": "7.57%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "7.58%",
                "statistical test": "chi-square test",
                "P-value": "0.021"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "BMI at age 20 <18.5",
                "n": "185",
                "percentage": "7.57%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "11.47%",
                "statistical test": "chi-square test",
                "P-value": "0.018"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "BMI at age 20 \u226518.5 but <22.5",
                "n": "185",
                "percentage": "60.54%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "64.85%",
                "statistical test": "chi-square test",
                "P-value": "0.018"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "BMI at age 20 \u226522.5 but <25",
                "n": "185",
                "percentage": "19.46%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "15.43%",
                "statistical test": "chi-square test",
                "P-value": "0.018"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "BMI at age 20 \u226525 but <27.5",
                "n": "185",
                "percentage": "5.95%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "4.91%",
                "statistical test": "chi-square test",
                "P-value": "0.018"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "BMI at age 20 \u226527.5",
                "n": "185",
                "percentage": "3.24%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "0.96%",
                "statistical test": "chi-square test",
                "P-value": "0.018"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "History of diabetes mellitus Yes",
                "n": "185",
                "percentage": "20.00%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "8.60%",
                "statistical test": "chi-square test",
                "P-value": "<0.001"
            }
        },
        {
            "subject": {
                "analysis": "Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls",
                "group": "Cases",
                "subgroup": "History of diabetes mellitus No",
                "n": "185",
                "percentage": "80.00%",
                "comparison group": "Controls",
                "comparison n": "1465",
                "comparison percentage": "91.40%",
                "statistical test": "chi-square test",
                "P-value": "<0.001"
            }
        }
    ],
    "PMC5762325_3": [
        {
            "subject": {
                "analysis": "Correlation analysis between E-cadherin and STYK1 expression in pancreatic cancer",
                "tumor tissue sample": "E-cadherin Low",
                "STYK1 expression": "Low",
                "count": "9"
            },
            "measures": "[]",
            "outcomes": ""
        },
        {
            "subject": {
                "analysis": "Correlation analysis between E-cadherin and STYK1 expression in pancreatic cancer",
                "tumor tissue sample": "E-cadherin Low",
                "STYK1 expression": "High",
                "count": "23"
            },
            "measures": "[]",
            "outcomes": ""
        },
        {
            "subject": {
                "analysis": "Correlation analysis between E-cadherin and STYK1 expression in pancreatic cancer",
                "tumor tissue sample": "E-cadherin Low",
                "correlation coefficient": "-0.420",
                "P-value": "<0.001"
            },
            "measures": "[]",
            "outcomes": ""
        },
        {
            "subject": {
                "analysis": "Correlation analysis between E-cadherin and STYK1 expression in pancreatic cancer",
                "tumor tissue sample": "E-cadherin High",
                "STYK1 expression": "Low",
                "count": "34"
            },
            "measures": "[]",
            "outcomes": ""
        },
        {
            "subject": {
                "analysis": "Correlation analysis between E-cadherin and STYK1 expression in pancreatic cancer",
                "tumor tissue sample": "E-cadherin High",
                "STYK1 expression": "High",
                "count": "14"
            },
            "measures": "[]",
            "outcomes": ""
        }
    ],
    "PMC3798558_3": [
        {
            "subject": {
                "analysis": "haplotype analysis for XRCC1",
                "haplotype": "CG",
                "SNP 1": "rs1799782",
                "SNP 2": "rs25487",
                "haplotype frequency (overall)": "0.439",
                "haplotype frequency (cases)": "0.433",
                "haplotype frequency (controls)": "0.442",
                "adjusted OR": "1.00 (ref.)",
                "P-value": "not reported",
                "method": "haplotype-effects logistic regression for case-control data",
                "adjustments": "multivariable adjustment by age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                "cases": "185",
                "controls": "1465"
            },
            "measures": "[]",
            "outcomes": ""
        },
        {
            "subject": {
                "analysis": "haplotype analysis for XRCC1",
                "haplotype": "CA",
                "SNP 1": "rs1799782",
                "SNP 2": "rs25487",
                "haplotype frequency (overall)": "0.240",
                "haplotype frequency (cases)": "0.274",
                "haplotype frequency (controls)": "0.239",
                "adjusted OR": "1.32 (1.01-1.71)",
                "P-value": "0.042",
                "method": "haplotype-effects logistic regression for case-control data",
                "adjustments": "multivariable adjustment by age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                "cases": "185",
                "controls": "1465"
            },
            "measures": "[R-squared value between rs1799782 and rs25487, OR]",
            "outcomes": "[0.15, 1.32]"
        },
        {
            "subject": {
                "analysis": "haplotype analysis for XRCC1",
                "haplotype": "TG",
                "SNP 1": "rs1799782",
                "SNP 2": "rs25487",
                "haplotype frequency (overall)": "0.319",
                "haplotype frequency (cases)": "0.292",
                "haplotype frequency (controls)": "0.318",
                "adjusted OR": "1.05 (0.81-1.36)",
                "P-value": "0.691",
                "method": "haplotype-effects logistic regression for case-control data",
                "adjustments": "multivariable adjustment by age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                "cases": "185",
                "controls": "1465"
            },
            "measures": "[]",
            "outcomes": ""
        },
        {
            "subject": {
                "analysis": "haplotype analysis for XRCC1",
                "haplotype": "TA",
                "SNP 1": "rs1799782",
                "SNP 2": "rs25487",
                "haplotype frequency (overall)": "0.002",
                "haplotype frequency (cases)": "<0.001",
                "haplotype frequency (controls)": "0.002",
                "adjusted OR": "N.E.",
                "P-value": "N.E.",
                "method": "haplotype-effects logistic regression for case-control data",
                "adjustments": "multivariable adjustment by age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                "cases": "185",
                "controls": "1465"
            },
            "measures": "[]",
            "outcomes": ""
        }
    ],
    "PMC4423458_3": [
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Fibrinogen beta chain isoform 1 pre-pro-protein",
                "accession": "70906435",
                "MW (kDa)": "56",
                "average SC in cancer": "138.8",
                "average SC in control": "52.1",
                "NSAF ratio": "2.2",
                "statistical test": "t-test",
                "P-value": "0.01481"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[138.8, 52.1, 2.2, 0.01481]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "C4b-binding protein alpha chain precursor",
                "accession": "4502503",
                "MW (kDa)": "67",
                "average SC in cancer": "37.3",
                "average SC in control": "11.5",
                "NSAF ratio": "2.3",
                "statistical test": "t-test",
                "P-value": "0.04311"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[37.3, 11.5, 2.3, 0.04311]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Serum albumin pre-pro-protein",
                "accession": "4502027",
                "MW (kDa)": "69",
                "average SC in cancer": "986.0",
                "average SC in control": "332.8",
                "NSAF ratio": "2.4",
                "statistical test": "t-test",
                "P-value": "0.00006"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[986.0, 332.8, 2.4, 0.00006]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Vitamin D-binding protein isoform 1 precursor",
                "accession": "32483410",
                "MW (kDa)": "53",
                "average SC in cancer": "51.9",
                "average SC in control": "19.2",
                "NSAF ratio": "2.4",
                "statistical test": "t-test",
                "P-value": "0.03919"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[51.9, 19.2, 2.4, 0.03919]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Kininogen-1 isoform 2 precursor",
                "accession": "4504893",
                "MW (kDa)": "48",
                "average SC in cancer": "21.3",
                "average SC in control": "5.5",
                "NSAF ratio": "3.8",
                "statistical test": "t-test",
                "P-value": "0.01109"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[21.3, 5.5, 3.8, 0.01109]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Alpha-2-macroglobulin precursor",
                "accession": "66932947",
                "MW (kDa)": "163",
                "average SC in cancer": "127.9",
                "average SC in control": "29.3",
                "NSAF ratio": "3.9",
                "statistical test": "t-test",
                "P-value": "0.00618"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[127.9, 29.3, 3.9, 0.00618]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Haptoglobin isoform 1 pre-pro-protein",
                "accession": "4826762",
                "MW (kDa)": "45",
                "average SC in cancer": "83.8",
                "average SC in control": "18.0",
                "NSAF ratio": "4.2",
                "statistical test": "t-test",
                "P-value": "0.00024"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[83.8, 18.0, 4.2, 0.00024]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Fibrinogen gamma chain isoform gamma-B precursor",
                "accession": "70906439",
                "MW (kDa)": "52",
                "average SC in cancer": "89.3",
                "average SC in control": "17.3",
                "NSAF ratio": "4.3",
                "statistical test": "t-test",
                "P-value": "0.00133"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[89.3, 17.3, 4.3, 0.00133]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Complement C3 precursor",
                "accession": "115298678",
                "MW (kDa)": "187",
                "average SC in cancer": "174.7",
                "average SC in control": "35.6",
                "NSAF ratio": "4.3",
                "statistical test": "t-test",
                "P-value": "0.00612"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[174.7, 35.6, 4.3, 0.00612]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Myeloperoxidase precursor",
                "accession": "4557759",
                "MW (kDa)": "84",
                "average SC in cancer": "70.2",
                "average SC in control": "11.0",
                "NSAF ratio": "5.3",
                "statistical test": "t-test",
                "P-value": "0.02501"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[70.2, 11.0, 5.3, 0.02501]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Apolipoprotein A-I pre-pro-protein",
                "accession": "4557321",
                "MW (kDa)": "31",
                "average SC in cancer": "29.8",
                "average SC in control": "5.9",
                "NSAF ratio": "5.7",
                "statistical test": "t-test",
                "P-value": "0.02170"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[29.8, 5.9, 5.7, 0.02170]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Fibrinogen alpha chain isoform alpha-E pre-pro-protein",
                "accession": "4503689",
                "MW (kDa)": "95",
                "average SC in cancer": "63.3",
                "average SC in control": "9.3",
                "NSAF ratio": "6.4",
                "statistical test": "t-test",
                "P-value": "0.00031"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[63.3, 9.3, 6.4, 0.00031]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Alpha-2-HS-glycoprotein pre-pro-protein",
                "accession": "156523970",
                "MW (kDa)": "39",
                "average SC in cancer": "7.3",
                "average SC in control": "1.1",
                "NSAF ratio": "6.5",
                "statistical test": "t-test",
                "P-value": "0.00173"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[7.3, 1.1, 6.5, 0.00173]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Ceruloplasmin precursor",
                "accession": "4557485",
                "MW (kDa)": "122",
                "average SC in cancer": "47.3",
                "average SC in control": "5.6",
                "NSAF ratio": "7.5",
                "statistical test": "t-test",
                "P-value": "0.00114"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[47.3, 5.6, 7.5, 0.00114]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "PREDICTED: complement C4-A isoform 1",
                "accession": "341916194",
                "MW (kDa)": "193",
                "average SC in cancer": "32.1",
                "average SC in control": "4.5",
                "NSAF ratio": "7.7",
                "statistical test": "t-test",
                "P-value": "0.01791"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[32.1, 4.5, 7.7, 0.01791]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Alpha-1B-glycoprotein precursor",
                "accession": "21071030",
                "MW (kDa)": "54",
                "average SC in cancer": "10.9",
                "average SC in control": "1.2",
                "NSAF ratio": "8.3",
                "statistical test": "t-test",
                "P-value": "0.00468"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[10.9, 1.2, 8.3, 0.00468]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor",
                "accession": "31542984",
                "MW (kDa)": "103",
                "average SC in cancer": "5.5",
                "average SC in control": "0.2",
                "NSAF ratio": "35.4",
                "statistical test": "t-test",
                "P-value": "0.00484"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[5.5, 0.2, 35.4, 0.00484]"
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "protein": "Apolipoprotein B-100 precursor",
                "accession": "105990532",
                "MW (kDa)": "516",
                "average SC in cancer": "49.3",
                "average SC in control": "1.0",
                "NSAF ratio": "55.7",
                "statistical test": "t-test",
                "P-value": "0.02595"
            },
            "measures": "[average SC in cancer, average SC in control, NSAF ratio, P-value]",
            "outcomes": "[49.3, 1.0, 55.7, 0.02595]"
        }
    ],
    "PMC5589562_2": [
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-145-5p",
                "accession number": "MIMAT0000437"
            },
            "measures": "[ratio]",
            "outcomes": "[8980.05]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-205-5p",
                "accession number": "MIMAT0000266"
            },
            "measures": "[ratio]",
            "outcomes": "[23077.19]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-199a-5p",
                "accession number": "MIMAT0000231"
            },
            "measures": "[ratio]",
            "outcomes": "[1563.68]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-200c-3p",
                "accession number": "MIMAT0000617"
            },
            "measures": "[ratio]",
            "outcomes": "[5968.64]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-199b-5p",
                "accession number": "MIMAT0000263"
            },
            "measures": "[ratio]",
            "outcomes": "[296.31]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-200b-3p",
                "accession number": "MIMAT0000318"
            },
            "measures": "[ratio]",
            "outcomes": "[467.15]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-136-5p",
                "accession number": "MIMAT0000448"
            },
            "measures": "[ratio]",
            "outcomes": "[228.24]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-429",
                "accession number": "MIMAT0001536"
            },
            "measures": "[ratio]",
            "outcomes": "[171.07]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-137",
                "accession number": "MIMAT0000429"
            },
            "measures": "[ratio]",
            "outcomes": "[227.70]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-196b-5p",
                "accession number": "MIMAT0001080"
            },
            "measures": "[ratio]",
            "outcomes": "[116.42]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-139-5p",
                "accession number": "MIMAT0000250"
            },
            "measures": "[ratio]",
            "outcomes": "[216.83]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-582-5p",
                "accession number": "MIMAT0003247"
            },
            "measures": "[ratio]",
            "outcomes": "[99.53]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-127-3p",
                "accession number": "MIMAT0000446"
            },
            "measures": "[ratio]",
            "outcomes": "[159.72]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-135b-5p",
                "accession number": "MIMAT0000758"
            },
            "measures": "[ratio]",
            "outcomes": "[87.82]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-337-5p",
                "accession number": "MIMAT0004695"
            },
            "measures": "[ratio]",
            "outcomes": "[148.57]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-182-5p",
                "accession number": "MIMAT0000259"
            },
            "measures": "[ratio]",
            "outcomes": "[55.81]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-139-3p",
                "accession number": "MIMAT0004552"
            },
            "measures": "[ratio]",
            "outcomes": "[146.36]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-96-5p",
                "accession number": "MIMAT0000095"
            },
            "measures": "[ratio]",
            "outcomes": "[53.82]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-487b",
                "accession number": "MIMAT0003180"
            },
            "measures": "[ratio]",
            "outcomes": "[118.72]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-200a-3p",
                "accession number": "MIMAT0000682"
            },
            "measures": "[ratio]",
            "outcomes": "[44.88]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-199a-3p+hsa-miR-199b-3p",
                "accession number": "MIMAT0000232"
            },
            "measures": "[ratio]",
            "outcomes": "[107.49]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-4284",
                "accession number": "MIMAT0016915"
            },
            "measures": "[ratio]",
            "outcomes": "[41.90]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-1233",
                "accession number": "MIMAT0005588"
            },
            "measures": "[ratio]",
            "outcomes": "[66.04]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-345-5p",
                "accession number": "MIMAT0000772"
            },
            "measures": "[ratio]",
            "outcomes": "[27.99]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-379-5p",
                "accession number": "MIMAT0000733"
            },
            "measures": "[ratio]",
            "outcomes": "[62.89]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-378g",
                "accession number": "MIMAT0018937"
            },
            "measures": "[ratio]",
            "outcomes": "[25.01]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-660-5p",
                "accession number": "MIMAT0003338"
            },
            "measures": "[ratio]",
            "outcomes": "[62.50]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-203",
                "accession number": "MIMAT0000264"
            },
            "measures": "[ratio]",
            "outcomes": "[22.43]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "TAS cells",
                "comparison to": "PC cells",
                "miRNA probe ID": "hsa-miR-335-5p",
                "accession number": "MIMAT0000765"
            },
            "measures": "[ratio]",
            "outcomes": "[60.53]"
        },
        {
            "subject": {
                "analysis": "differential expression analysis of miRNAs",
                "context": "PC cells",
                "comparison to": "TAS cells",
                "miRNA probe ID": "hsa-miR-141-3p",
                "accession number": "MIMAT0000432"
            },
            "measures": "[ratio]",
            "outcomes": "[21.69]"
        }
    ],
    "PMC4190529_6": [
        {
            "subject": {
                "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                "treatment": "gemcitabine",
                "control": "5-fluorouracil",
                "phase": "3",
                "median survival therapy": "5.7 months",
                "median survival control": "4.2 months",
                "one-year survival therapy": "18%",
                "one-year survival control": "2%",
                "side effects": "more favorable than 5-fluorouracil",
                "FDA approval": "1996"
            },
            "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
            "outcomes": "[5.7, 4.2, 18%, 2%]"
        },
        {
            "subject": {
                "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                "control": "gemcitabine",
                "phase": "3",
                "median survival therapy": "6.4 months",
                "median survival control": "6 months",
                "one-year survival therapy": "24%",
                "one-year survival control": "19%",
                "side effects": "less favorable than gemcitabine",
                "FDA approval": "2005"
            },
            "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
            "outcomes": "[6.4, 6, 24%, 19%]"
        },
        {
            "subject": {
                "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                "control": "gemcitabine",
                "phase": "3",
                "median survival therapy": "8.5 months",
                "median survival control": "6.7 months",
                "one-year survival therapy": "35%",
                "one-year survival control": "22%",
                "side effects": "less favorable than gemcitabine",
                "FDA approval": "2013"
            },
            "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
            "outcomes": "[8.5, 6.7, 35%, 22%]"
        },
        {
            "subject": {
                "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                "treatment": "FOLFIRINOX",
                "control": "gemcitabine",
                "phase": "2/3",
                "median survival therapy": "11.1 months",
                "median survival control": "6.8 months",
                "one-year survival therapy": "48.4%",
                "one-year survival control": "20.6%",
                "side effects": "less favorable than gemcitabine",
                "FDA approval": "n/a",
                "components": "Oxaliplatin, irinotecan, fluorouracil and leucovorin"
            },
            "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
            "outcomes": "[11.1, 6.8, 48.4%, 20.6%]"
        },
        {
            "subject": {
                "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                "treatment": "cell encapsulation + ifosfamide",
                "control": "5-fluorouracil",
                "phase": "2",
                "median survival therapy": "10 months",
                "median survival control": "5 months",
                "one-year survival therapy": "36%",
                "one-year survival control": "18%",
                "side effects": "more favorable than 5-fluorouracil or gemcitabine",
                "FDA approval": "n/a",
                "toxicity": "five patients experienced Grade 3 or Grade 4 NCI toxicities with a higher dose of 2 g/m2",
                "median survival": "9.5 months"
            },
            "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
            "outcomes": "[10, 5, 36%, 18%]"
        }
    ],
    "PMC5675623_3": [
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "objective": "assess impact of multiple factors on overall survival (OS)",
                "variable": "ECOG performance status",
                "contrast": "> 0 vs. 0",
                "hazard ratio": "1.47 (0.90, 2.41)",
                "P value": "0.12"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.47 (0.90, 2.41), 0.12]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "objective": "assess impact of multiple factors on overall survival (OS)",
                "variable": "Liver metastases",
                "contrast": "Yes vs. No",
                "hazard ratio": "1.72 (1.01, 2.91)",
                "P value": "0.045"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.72 (1.01, 2.91), 0.045]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "objective": "assess impact of multiple factors on overall survival (OS)",
                "variable": "No. of metastatic sites",
                "contrast": ">2 vs. <= 2",
                "hazard ratio": "1.33 (0.9, 2.25)",
                "P value": "0.28"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.33 (0.9, 2.25), 0.28]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "objective": "assess impact of multiple factors on overall survival (OS)",
                "variable": "Prior radiation therapy",
                "contrast": "Yes vs. No",
                "hazard ratio": "1.58 (0.95, 2.61)",
                "P value": "0.077"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.58 (0.95, 2.61), 0.077]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "objective": "assess impact of multiple factors on overall survival (OS)",
                "variable": "Prior FOLFIRINOX",
                "contrast": "Yes vs. No",
                "hazard ratio": "1.73 (1.01, 2.98)",
                "P value": "0.046",
                "treatment": "FOLFIRINOX"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.73 (1.01, 2.98), 0.046]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "objective": "assess impact of multiple factors on overall survival (OS)",
                "variable": "Prior gemcitabine plus nab-paclitaxel treatment",
                "contrast": "Yes vs. No",
                "hazard ratio": "1.08 (0.58, 2.01)",
                "P value": "0.80"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.08 (0.58, 2.01), 0.80]"
        }
    ],
    "PMC4742219_3": [
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Age",
                "HR": "1.00 (0.98, 1.02)",
                "P value": "0.874",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[1.00 (0.98, 1.02), 0.874]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Gender (female vs. male)",
                "HR": "0.89 (0.60, 1.31)",
                "P value": "0.544",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[0.89 (0.60, 1.31), 0.544]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Tumor size",
                "HR": "1.13 (0.97, 1.33)",
                "P value": "0.127",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[1.13 (0.97, 1.33), 0.127]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Tumor grade",
                "comparison": "Grade II vs. I",
                "HR": "1.00 (0.69, 1.45)",
                "P value": "0.991",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[1.00 (0.69, 1.45), 0.991]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Tumor grade",
                "comparison": "Grade III vs. I",
                "HR": "0.93 (0.27, 3.17)",
                "P value": "0.906",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[0.93 (0.27, 3.17), 0.906]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Lymph Nodes (yes vs. no)",
                "HR": "1.39 (0.81, 2.38)",
                "P value": "0.229",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[1.39 (0.81, 2.38), 0.229]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Margin (positive vs. negative)",
                "HR": "1.54 (1.06, 2.25)",
                "P value": "0.025",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[1.54 (1.06, 2.25), 0.025]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Vascular invasion (yes vs. no)",
                "HR": "0.99 (0.69, 1.42)",
                "P value": "0.967",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[0.99 (0.69, 1.42), 0.967]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Perineural invasion (yes vs. no)",
                "HR": "2.19 (0.87, 5.49)",
                "P value": "0.097",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[2.19 (0.87, 5.49), 0.097]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Time from surgery to first recurrence",
                "HR": "1.00 (0.98, 1.02)",
                "P value": "0.883",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[1.00 (0.98, 1.02), 0.883]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Recurrence pattern",
                "comparison": "Lung + Other vs. Lung",
                "HR": "1.25 (0.63, 2.48)",
                "P value": "0.516",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[1.25 (0.63, 2.48), 0.516]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Recurrence pattern",
                "comparison": "Liver + Other vs. Lung",
                "HR": "1.91 (1.10, 3.31)",
                "P value": "0.022",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[1.91 (1.10, 3.31), 0.022]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Recurrence pattern",
                "comparison": "Peritoneal vs. Lung",
                "HR": "6.32 (3.12, 12.79)",
                "P value": "< 0.001",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[6.32 (3.12, 12.79), < 0.001]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Recurrence pattern",
                "comparison": "Local vs. Lung",
                "HR": "2.09 (1.10, 4.00)",
                "P value": "0.025",
                "statistical measure": "hazard ratio (HR)",
                "confidence interval": "95% CI"
            },
            "measures": "[HR, P value]",
            "outcomes": "[2.09 (1.10, 4.00), 0.025]"
        }
    ],
    "PMC4941379_3": [
        {
            "subject": {
                "analysis": "Risk of gastric cancer incidence by chronic atrophic gastritis, H. pylori infection and CagA seropositivity",
                "chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG\u2212/CagA\u2212",
                "sample size": "4,555",
                "cases": "5",
                "crude incidence rate (per 100": "000 person-years), 10.42",
                "HR1 (95% CI)": "Ref",
                "HR2 (95% CI)": "Ref"
            },
            "measures": "[metric, crude incidence rate]",
            "outcomes": "[outcome, 10.42]"
        },
        {
            "subject": {
                "analysis": "Risk of gastric cancer incidence by chronic atrophic gastritis, H. pylori infection and CagA seropositivity",
                "chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA\u2212",
                "sample size": "1,984",
                "cases": "2",
                "crude incidence rate (per 100": "000 person-years), 9.54",
                "HR1 (95% CI)": "0.79 (0.15\u20134.08)",
                "HR2 (95% CI)": "Ref"
            },
            "measures": "[metric, crude incidence rate]",
            "outcomes": "[outcome, 9.54]"
        },
        {
            "subject": {
                "analysis": "Risk of gastric cancer incidence by chronic atrophic gastritis, H. pylori infection and CagA seropositivity",
                "chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "sample size": "2,295",
                "cases": "14",
                "crude incidence rate (per 100": "000 person-years), 58.13",
                "HR1 (95% CI)": "5.05 (1.81\u201314.09)",
                "HR2 (95% CI)": "Ref"
            },
            "measures": "[metric, crude incidence rate]",
            "outcomes": "[outcome, 58.13]"
        },
        {
            "subject": {
                "analysis": "Risk of gastric cancer incidence by chronic atrophic gastritis, H. pylori infection and CagA seropositivity",
                "chronic atrophic gastritis": "Present",
                "H. pylori infection": "IgG\u2212/CagA\u2212",
                "sample size": "205",
                "cases": "0",
                "crude incidence rate (per 100": "000 person-years), 0",
                "HR1 (95% CI)": "3.45 (1.38\u20138.64)",
                "HR2 (95% CI)": "Not estimable"
            },
            "measures": "[metric, crude incidence rate]",
            "outcomes": "[outcome, 0]"
        },
        {
            "subject": {
                "analysis": "Risk of gastric cancer incidence by chronic atrophic gastritis, H. pylori infection and CagA seropositivity",
                "chronic atrophic gastritis": "Present",
                "H. pylori infection": "IgG+/CagA\u2212",
                "sample size": "143",
                "cases": "1",
                "crude incidence rate (per 100": "000 person-years), 64.61",
                "HR1 (95% CI)": "5.50 (0.63\u201347.57)",
                "HR2 (95% CI)": "Not estimable"
            },
            "measures": "[metric, crude incidence rate]",
            "outcomes": "[outcome, 64.61]"
        },
        {
            "subject": {
                "analysis": "Risk of gastric cancer incidence by chronic atrophic gastritis, H. pylori infection and CagA seropositivity",
                "chronic atrophic gastritis": "Present",
                "H. pylori infection": "IgG+/CagA+",
                "sample size": "315",
                "cases": "5",
                "crude incidence rate (per 100": "000 person-years), 151.20",
                "HR1 (95% CI)": "12.51 (3.57\u201343.22)",
                "HR2 (95% CI)": "Not estimable"
            },
            "measures": "[metric, crude incidence rate]",
            "outcomes": "[outcome, 151.20]"
        }
    ],
    "PMC3987090_4": [
        {
            "subject": {
                "analysis": "relationship with survival",
                "threshold": "NLR \u22641",
                "group size": "14 (5.6%)",
                "median OS": "12.8 (9.4\u201316.2) months",
                "hazard ratio (univariate)": "1",
                "95% CI (univariate)": "0.86\u20133.29",
                "P-value (univariate)": "0.13",
                "hazard ratio (multivariate)": "1",
                "95% CI (multivariate)": "0.69\u20132.71",
                "P-value (multivariate)": "0.37"
            },
            "measures": "[median OS, hazard ratio (univariate), hazard ratio (multivariate)]",
            "outcomes": "[12.8 (9.4\u201316.2), 1, 1]"
        },
        {
            "subject": {
                "analysis": "relationship with survival",
                "threshold": "NLR >1",
                "group size": "238 (94.4%)",
                "median OS": "11.7 (10.4\u201313.0) months",
                "hazard ratio (univariate)": "1.68",
                "hazard ratio (multivariate)": "1.37"
            },
            "measures": "[median OS, hazard ratio (univariate), hazard ratio (multivariate)]",
            "outcomes": "[11.7 (10.4\u201313.0), 1.68, 1.37]"
        },
        {
            "subject": {
                "analysis": "relationship with survival",
                "threshold": "NLR \u22642",
                "group size": "83 (32.9%)",
                "median OS": "14.8 (11.5\u201318.2) months",
                "hazard ratio (univariate)": "1",
                "95% CI (univariate)": "1.13\u20132.05",
                "P-value (univariate)": "0.01",
                "hazard ratio (multivariate)": "1",
                "95% CI (multivariate)": "0.88\u20131.66",
                "P-value (multivariate)": "0.24"
            },
            "measures": "[median OS, hazard ratio (univariate), hazard ratio (multivariate)]",
            "outcomes": "[14.8 (11.5\u201318.2), 1, 1]"
        },
        {
            "subject": {
                "analysis": "relationship with survival",
                "threshold": "NLR >2",
                "group size": "169 (67.1%)",
                "median OS": "10.7 (9.3\u201312.1) months",
                "hazard ratio (univariate)": "1.52",
                "hazard ratio (multivariate)": "1.21"
            },
            "measures": "[median OS, hazard ratio (univariate), hazard ratio (multivariate)]",
            "outcomes": "[10.7 (9.3\u201312.1), 1.52, 1.21]"
        },
        {
            "subject": {
                "analysis": "relationship with survival",
                "threshold": "NLR \u22643",
                "group size": "158 (62.7%)",
                "median OS": "13.4 (11.1\u201315.7) months",
                "hazard ratio (univariate)": "1",
                "95% CI (univariate)": "1.26\u20132.23",
                "P-value (univariate)": "<0.01",
                "hazard ratio (multivariate)": "1",
                "95% CI (multivariate)": "1.18\u20132.11",
                "P-value (multivariate)": "<0.01"
            },
            "measures": "[median OS, hazard ratio (univariate), hazard ratio (multivariate)]",
            "outcomes": "[13.4 (11.1\u201315.7), 1, 1]"
        },
        {
            "subject": {
                "analysis": "relationship with survival",
                "threshold": "NLR >3",
                "group size": "94 (37.3%)",
                "median OS": "8.6 (6.2\u201311.0) months",
                "hazard ratio (univariate)": "1.68",
                "hazard ratio (multivariate)": "1.57"
            },
            "measures": "[median OS, hazard ratio (univariate), hazard ratio (multivariate)]",
            "outcomes": "[8.6 (6.2\u201311.0), 1.68, 1.57]"
        },
        {
            "subject": {
                "analysis": "relationship with survival",
                "threshold": "NLR \u22644",
                "group size": "194 (77.0%)",
                "median OS": "13.3 (11.4\u201315.2) months",
                "hazard ratio (univariate)": "1",
                "95% CI (univariate)": "1.44\u20132.78",
                "P-value (univariate)": "<0.01",
                "hazard ratio (multivariate)": "1",
                "95% CI (multivariate)": "1.36\u20132.67",
                "P-value (multivariate)": "<0.01"
            },
            "measures": "[median OS, hazard ratio (univariate), hazard ratio (multivariate)]",
            "outcomes": "[13.3 (11.4\u201315.2), 1, 1]"
        },
        {
            "subject": {
                "analysis": "relationship with survival",
                "threshold": "NLR >4",
                "group size": "58 (23.0%)",
                "median OS": "7.3 (5.6\u20139.0) months",
                "hazard ratio (univariate)": "2.00",
                "hazard ratio (multivariate)": "1.91"
            },
            "measures": "[median OS, hazard ratio (univariate), hazard ratio (multivariate)]",
            "outcomes": "[7.3 (5.6\u20139.0), 2.00, 1.91]"
        },
        {
            "subject": {
                "analysis": "relationship with survival",
                "threshold": "NLR \u22645",
                "group size": "212 (84.1%)",
                "median OS": "12.8 (10.7\u201314.9) months",
                "hazard ratio (univariate)": "1",
                "95% CI (univariate)": "1.50\u20133.15",
                "P-value (univariate)": "<0.01",
                "hazard ratio (multivariate)": "1",
                "95% CI (multivariate)": "1.49\u20133.15",
                "P-value (multivariate)": "<0.01"
            },
            "measures": "[median OS, hazard ratio (univariate), hazard ratio (multivariate)]",
            "outcomes": "[12.8 (10.7\u201314.9), 1, 1]"
        },
        {
            "subject": {
                "analysis": "relationship with survival",
                "threshold": "NLR >5",
                "group size": "40 (15.9%)",
                "median OS": "6.0 (2.8\u20139.2) months",
                "hazard ratio (univariate)": "2.17",
                "hazard ratio (multivariate)": "2.16"
            },
            "measures": "[median OS, hazard ratio (univariate), hazard ratio (multivariate)]",
            "outcomes": "[6.0 (2.8\u20139.2), 2.17, 2.16]"
        }
    ],
    "PMC3987090_5": [
        {
            "subject": {
                "study": "An X et al.",
                "year": "2010",
                "sample size": "89",
                "proportion of patients with pretreatment NLR >5": "16 (17.9%)",
                "overall survival comparison (NLR >5 vs. \u22645)": "2.4 versus 7.7 months",
                "hazard ratio (NLR \u22645 was set at 1)": "HR = 4.49",
                "P-value": "0.013",
                "association": "elevated NLR as independent prognostic factor for OS in APC patients receiving chemotherapy"
            },
            "measures": "[hazard ratio, P-value]",
            "outcomes": "[4.49, 0.013]"
        },
        {
            "subject": {
                "study": "Wang DS et al.",
                "year": "2012",
                "sample size": "86",
                "proportion of patients with pretreatment NLR >5": "12 (13.9%)",
                "overall survival comparison (NLR >5 vs. \u22645)": "5.8 versus 10.2 months",
                "association": "elevated NLR as independent prognostic factor for OS in APC patients receiving chemotherapy"
            }
        },
        {
            "subject": {
                "study": "Stotz M et al.",
                "year": "2013",
                "sample size": "261",
                "proportion of patients with pretreatment NLR >5": "79 (30.3%)",
                "hazard ratio (NLR \u22645 was set at 1)": "HR = 2.53",
                "P-value": "<0.01",
                "association": "elevated NLR as independent prognostic factor for OS in APC patients receiving chemotherapy",
                "study design": "pooled data from patients receiving chemotherapy (n = 179) and no chemotherapy (n = 82)"
            },
            "measures": "[hazard ratio, P-value]",
            "outcomes": "[2.53, <0.01]"
        },
        {
            "subject": {
                "study": "Our study",
                "year": "2013",
                "sample size": "253",
                "proportion of patients with pretreatment NLR >5": "40 (15.8%)",
                "overall survival comparison (NLR >5 vs. \u22645)": "6.0 versus 12.8 months",
                "hazard ratio (NLR \u22645 was set at 1)": "HR = 1.95",
                "P-value": "<0.01",
                "association": "elevated NLR as independent prognostic factor for OS in APC patients receiving chemotherapy"
            },
            "measures": "[hazard ratio, P-value]",
            "outcomes": "[1.95, <0.01]"
        }
    ],
    "PMC3544459_4": [
        {
            "subject": {
                "analysis": "Overall survival and risk of death by clinical characteristics",
                "condition": "Diabetes",
                "group": "No",
                "median survival time (months)": "33.2 \u00b1 1.8",
                "comparison": "Yes",
                "statistical test": "log-rank",
                "univariate HR (95% CI)": "1.0",
                "univariate P value": "0.049",
                "multivariate HR (95% CI)": "1.0",
                "multivariate P value": "0.050"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "analysis": "Overall survival and risk of death by clinical characteristics",
                "condition": "Diabetes",
                "group": "Yes",
                "median survival time (months)": "24.6 \u00b1 2.5",
                "comparison": "No",
                "statistical test": "log-rank",
                "univariate HR (95% CI)": "1.27 (1.00\u20131.60)",
                "univariate P value": "0.049",
                "multivariate HR (95% CI)": "1.29 (1.02\u20131.64)",
                "multivariate P value": "0.036"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "analysis": "Overall survival and risk of death by clinical characteristics",
                "condition": "Perineural invasion",
                "group": "No",
                "median survival time (months)": "51.7 \u00b1 31.1",
                "comparison": "Yes",
                "statistical test": "log-rank",
                "univariate HR (95% CI)": "1.0",
                "univariate P value": "<0.001",
                "multivariate HR (95% CI)": "1.0",
                "multivariate P value": "<0.001"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "analysis": "Overall survival and risk of death by clinical characteristics",
                "condition": "Perineural invasion",
                "group": "Yes",
                "median survival time (months)": "29.4 \u00b1 1.64",
                "comparison": "No",
                "statistical test": "log-rank",
                "univariate HR (95% CI)": "2.01 (1.38\u20132.93)",
                "univariate P value": "<0.001",
                "multivariate HR (95% CI)": "1.60 (1.08\u20132.36)",
                "multivariate P value": "0.019"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "analysis": "Overall survival and risk of death by clinical characteristics",
                "condition": "Margin status",
                "group": "Negative",
                "median survival time (months)": "33.6 \u00b1 1.7",
                "comparison": "Positive",
                "statistical test": "log-rank",
                "univariate HR (95% CI)": "1.0",
                "univariate P value": "<0.001",
                "multivariate HR (95% CI)": "1.0",
                "multivariate P value": "<0.001"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "analysis": "Overall survival and risk of death by clinical characteristics",
                "condition": "Margin status",
                "group": "Positive",
                "median survival time (months)": "24.8 \u00b1 2.6",
                "comparison": "Negative",
                "statistical test": "log-rank",
                "univariate HR (95% CI)": "1.62 (1.27\u20132.08)",
                "univariate P value": "<0.001",
                "multivariate HR (95% CI)": "1.47 (1.14\u20131.90)",
                "multivariate P value": "0.003"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "analysis": "Overall survival and risk of death by clinical characteristics",
                "condition": "Node status",
                "group": "Negative",
                "median survival time (months)": "38.6 \u00b1 5.3",
                "comparison": "Positive",
                "statistical test": "log-rank",
                "univariate HR (95% CI)": "1.0",
                "univariate P value": "<0.001",
                "multivariate HR (95% CI)": "1.0",
                "multivariate P value": "<0.001"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "analysis": "Overall survival and risk of death by clinical characteristics",
                "condition": "Node status",
                "group": "Positive",
                "median survival time (months)": "27.5 \u00b1 1.3",
                "comparison": "Negative",
                "statistical test": "log-rank",
                "univariate HR (95% CI)": "1.70 (1.35\u20132.15)",
                "univariate P value": "<0.001",
                "multivariate HR (95% CI)": "1.45 (1.14\u20131.83)",
                "multivariate P value": "0.002"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "analysis": "Overall survival and risk of death by clinical characteristics",
                "condition": "Differentiation",
                "group": "Well\u2013moderate",
                "median survival time (months)": "35.9 \u00b1 2.68",
                "comparison": "Poor",
                "statistical test": "log-rank",
                "univariate HR (95% CI)": "1.0",
                "univariate P value": "<0.001",
                "multivariate HR (95% CI)": "1.0",
                "multivariate P value": "<0.001"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "analysis": "Overall survival and risk of death by clinical characteristics",
                "condition": "Differentiation",
                "group": "Poor",
                "median survival time (months)": "26.0 \u00b1 1.77",
                "comparison": "Well\u2013moderate",
                "statistical test": "log-rank",
                "univariate HR (95% CI)": "1.63 (1.32\u20132.02)",
                "univariate P value": "<0.001",
                "multivariate HR (95% CI)": "1.63 (1.32\u20132.02)",
                "multivariate P value": "<0.001"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        }
    ],
    "PMC3497287_3": [
        {
            "subject": {
                "analysis": "inherited pancreatic cancer syndromes",
                "syndrome": "Lynch Syndrome",
                "mutated gene": "Mismatch Repair Genes (MMR): MLH1, MSH2, MSH6 and PMS2"
            }
        },
        {
            "subject": {
                "analysis": "inherited pancreatic cancer syndromes",
                "syndrome": "Peutz-Jeghers Syndrome",
                "mutated gene": "STK11/LKB1"
            }
        },
        {
            "subject": {
                "analysis": "inherited pancreatic cancer syndromes",
                "syndrome": "Hereditary Breast Cancer",
                "mutated gene": "BRCA1/BRCA2"
            }
        },
        {
            "subject": {
                "analysis": "inherited pancreatic cancer syndromes",
                "syndrome": "Familial Atypical Multiple Mole Melanoma",
                "mutated gene": "CDKN2A mutation"
            }
        }
    ],
    "PMC4728116_3": [
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "Family history of pancreatic cancer",
                "group": "No",
                "cases (n)": "312",
                "cases (%)": "\u221296.6",
                "controls (n)": "320",
                "controls (%)": "\u221299.1",
                "crude OR (95% CI)": "1.00 (reference)",
                "adjusted OR1 (95% CI)": "1.00 (reference)",
                "adjusted OR2 (95% CI)": "1.00 (reference)"
            }
        },
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "Family history of pancreatic cancer",
                "group": "Yes",
                "cases (n)": "11",
                "cases (%)": "\u22123.4",
                "controls (n)": "3",
                "controls (%)": "\u22120.9",
                "crude OR (95% CI)": "3.67 (1.02\u201313.14)",
                "adjusted OR1 (95% CI)": "4.04 (1.08\u201315.07)",
                "adjusted OR2 (95% CI)": "1.23 (1.11\u20133.70)"
            }
        },
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "BMI",
                "group": "<24.0",
                "cases (n)": "197",
                "cases (%)": "\u221261.0",
                "controls (n)": "230",
                "controls (%)": "\u221271.2",
                "crude OR (95% CI)": "1.00 (reference)",
                "adjusted OR1 (95% CI)": "1.00 (reference)",
                "adjusted OR2 (95% CI)": "1.00 (reference)"
            }
        },
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "BMI",
                "group": "\u226524.0",
                "cases (n)": "126",
                "cases (%)": "\u221239.0",
                "controls (n)": "93",
                "controls (%)": "\u221228.8",
                "crude OR (95% CI)": "1.67 (1.18\u20132.38)",
                "adjusted OR1 (95% CI)": "1.78 (1.23\u20132.58)",
                "adjusted OR2 (95% CI)": "1.77 (1.22\u20132.57)"
            }
        },
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "Diabetes",
                "group": "No",
                "cases (n)": "174",
                "cases (%)": "\u221278.0",
                "controls (n)": "255",
                "controls (%)": "\u221290.7",
                "crude OR (95% CI)": "1.00 (reference)",
                "adjusted OR1 (95% CI)": "1.00 (reference)",
                "adjusted OR2 (95% CI)": "1.00 (reference)"
            }
        },
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "Diabetes",
                "group": "Yes",
                "cases (n)": "49",
                "cases (%)": "\u221222.0",
                "controls (n)": "26",
                "controls (%)": "\u22129.3",
                "crude OR (95% CI)": "2.69 (1.51\u20134.77)",
                "adjusted OR1 (95% CI)": "2.60 (1.41\u20134.79)",
                "adjusted OR2 (95% CI)": "2.96 (1.48\u20135.92)"
            }
        },
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "Cholecystitis",
                "group": "No",
                "cases (n)": "272",
                "cases (%)": "\u221294.1",
                "controls (n)": "195",
                "controls (%)": "\u221296.7",
                "crude OR (95% CI)": "1.00 (reference)",
                "adjusted OR1 (95% CI)": "1.00 (reference)",
                "adjusted OR2 (95% CI)": "1.00 (reference)"
            }
        },
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "Cholecystitis",
                "group": "Yes",
                "cases (n)": "17",
                "cases (%)": "\u22125.9",
                "controls (n)": "10",
                "controls (%)": "\u22123.3",
                "crude OR (95% CI)": "1.89 (0.84\u20134.24)",
                "adjusted OR1 (95% CI)": "1.91 (0.83\u20134.38)",
                "adjusted OR2 (95% CI)": "1.35 (0.50\u20133.68)"
            }
        },
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "Gallstone",
                "group": "No",
                "cases (n)": "274",
                "cases (%)": "\u221295.1",
                "controls (n)": "300",
                "controls (%)": "\u221298.4",
                "crude OR (95% CI)": "1.00 (reference)",
                "adjusted OR1 (95% CI)": "1.00 (reference)",
                "adjusted OR2 (95% CI)": "1.00 (reference)"
            }
        },
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "Gallstone",
                "group": "Yes",
                "cases (n)": "14",
                "cases (%)": "\u22124.9",
                "controls (n)": "5",
                "controls (%)": "\u22121.6",
                "crude OR (95% CI)": "2.80 (1.01\u20137.77)",
                "adjusted OR1 (95% CI)": "2.58 (0.89\u20137.44)",
                "adjusted OR2 (95% CI)": "2.68 (0.65\u201311.07)"
            }
        }
    ],
    "PMC4741511_2": [
        {
            "subject": {
                "study": "MAPS phase II",
                "analysis": "PFS and OS",
                "population subgroup": "Sorafenib group",
                "LDH level": "LDH \u2264 UNR",
                "treatment": "chemotherapy plus sorafenib",
                "patients number": "31",
                "patients percentage": "44%",
                "PFS (months)": "7.6",
                "OS (months)": "12.7",
                "PFS p-value": "0.05",
                "OS p-value": "0.0012"
            },
            "measures": "[PFS (months), OS (months)]",
            "outcomes": "[7.6, 12.7]"
        },
        {
            "subject": {
                "study": "MAPS phase II",
                "analysis": "PFS and OS",
                "population subgroup": "Sorafenib group",
                "LDH level": "LDH > UNR",
                "treatment": "chemotherapy plus sorafenib",
                "patients number": "6",
                "patients percentage": "8%",
                "PFS (months)": "2.8",
                "OS (months)": "5.9",
                "PFS p-value": "0.05",
                "OS p-value": "0.0012"
            },
            "measures": "[PFS (months), OS (months)]",
            "outcomes": "[2.8, 5.9]"
        },
        {
            "subject": {
                "study": "MAPS phase II",
                "analysis": "PFS and OS",
                "population subgroup": "No Sorafenib group",
                "LDH level": "LDH \u2264 UNR",
                "treatment": "chemotherapy alone",
                "patients number": "27",
                "patients percentage": "38%",
                "PFS (months)": "3.3",
                "OS (months)": "8.6",
                "PFS p-value": "0.05",
                "OS p-value": "0.0012"
            },
            "measures": "[PFS (months), OS (months)]",
            "outcomes": "[3.3, 8.6]"
        },
        {
            "subject": {
                "study": "MAPS phase II",
                "analysis": "PFS and OS",
                "population subgroup": "No Sorafenib group",
                "LDH level": "LDH > UNR",
                "treatment": "chemotherapy alone",
                "patients number": "7",
                "patients percentage": "10%",
                "PFS (months)": "2.2",
                "OS (months)": "5.2",
                "PFS p-value": "0.05",
                "OS p-value": "0.0012"
            },
            "measures": "[PFS (months), OS (months)]",
            "outcomes": "[2.2, 5.2]"
        }
    ],
    "PMC5522086_3": [
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "TP53",
                "activation z-score": "\u22122.353",
                "overlap P-value": "3.34\u00d710^\u221232"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[\u22122.353, 3.34\u00d710^\u221232]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "NUPR1",
                "log ratio": "\u22122.52",
                "activation z-score": "\u22123.977",
                "overlap P-value": "4.62\u00d710^\u221213"
            },
            "measures": "[log ratio, activation z-score, overlap P-value]",
            "outcomes": "[\u22122.52, \u22123.977, 4.62\u00d710^\u221213]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "NKX2-3",
                "activation z-score": "\u22123.455",
                "overlap P-value": "5.88\u00d710^\u221212"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[\u22123.455, 5.88\u00d710^\u221212]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "HNF1A",
                "activation z-score": "\u22122.359",
                "overlap P-value": "8.82\u00d710^\u221212"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[\u22122.359, 8.82\u00d710^\u221212]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "CDKN2A",
                "log ratio": "1.737",
                "activation z-score": "\u22123.219",
                "overlap P-value": "1.34\u00d710^\u221211"
            },
            "measures": "[log ratio, activation z-score, overlap P-value]",
            "outcomes": "[1.737, \u22123.219, 1.34\u00d710^\u221211]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "estrogen receptor",
                "activation z-score": "\u22122.299",
                "overlap P-value": "9.57\u00d710^\u221210"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[\u22122.299, 9.57\u00d710^\u221210]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "RB1",
                "activation z-score": "\u22124.286",
                "overlap P-value": "3.74\u00d710^\u221208"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[\u22124.286, 3.74\u00d710^\u221208]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "TCF3",
                "activation z-score": "\u22123.116",
                "overlap P-value": "4.32\u00d710^\u221208"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[\u22123.116, 4.32\u00d710^\u221208]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "TRIM24",
                "activation z-score": "\u22123.714",
                "overlap P-value": "6.26\u00d710^\u221207"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[\u22123.714, 6.26\u00d710^\u221207]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "BCL6",
                "activation z-score": "\u22122.313",
                "overlap P-value": "1.60\u00d710^\u221206"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[\u22122.313, 1.60\u00d710^\u221206]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "NR5A2",
                "log ratio": "\u22122.876",
                "activation z-score": "\u22122.7",
                "overlap P-value": "7.26\u00d710^\u221206"
            },
            "measures": "[log ratio, activation z-score, overlap P-value]",
            "outcomes": "[\u22122.876, \u22122.7, 7.26\u00d710^\u221206]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "SATB1",
                "log ratio": "\u22120.814",
                "activation z-score": "\u22122.003",
                "overlap P-value": "1.09\u00d710^\u221205"
            },
            "measures": "[log ratio, activation z-score, overlap P-value]",
            "outcomes": "[\u22120.814, \u22122.003, 1.09\u00d710^\u221205]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "IRF4",
                "log ratio": "2.115",
                "activation z-score": "\u22122.41",
                "overlap P-value": "4.24\u00d710^\u221205"
            },
            "measures": "[log ratio, activation z-score, overlap P-value]",
            "outcomes": "[2.115, \u22122.41, 4.24\u00d710^\u221205]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "RBL1",
                "activation z-score": "\u22123.124",
                "overlap P-value": "1.72\u00d710^\u221204"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[\u22123.124, 1.72\u00d710^\u221204]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "inhibition",
                "transcription regulator": "SPDEF",
                "activation z-score": "\u22122.887",
                "overlap P-value": "2.39\u00d710^\u221204"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[\u22122.887, 2.39\u00d710^\u221204]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "STAT3",
                "activation z-score": "2.924",
                "overlap P-value": "5.78\u00d710^\u221219"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[2.924, 5.78\u00d710^\u221219]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "CTNNB1",
                "activation z-score": "3.359",
                "overlap P-value": "1.99\u00d710^\u221215"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[3.359, 1.99\u00d710^\u221215]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "SP1",
                "activation z-score": "2.06",
                "overlap P-value": "4.79\u00d710^\u221213"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[2.06, 4.79\u00d710^\u221213]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "CEBPB",
                "activation z-score": "2.866",
                "overlap P-value": "2.62\u00d710^\u221212"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[2.866, 2.62\u00d710^\u221212]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "NFkB (complex)",
                "activation z-score": "6.314",
                "overlap P-value": "1.43\u00d710^\u221211"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[6.314, 1.43\u00d710^\u221211]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "TBX2",
                "activation z-score": "4.99",
                "overlap P-value": "1.62\u00d710^\u221211"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[4.99, 1.62\u00d710^\u221211]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "IRF1",
                "activation z-score": "3.759",
                "overlap P-value": "2.76\u00d710^\u221211"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[3.759, 2.76\u00d710^\u221211]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "IRF7",
                "log ratio": "1.504",
                "activation z-score": "5.591",
                "overlap P-value": "2.88\u00d710^\u221210"
            },
            "measures": "[log ratio, activation z-score, overlap P-value]",
            "outcomes": "[1.504, 5.591, 2.88\u00d710^\u221210]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "FOXM1",
                "log ratio": "2.152",
                "activation z-score": "4.395",
                "overlap P-value": "5.12\u00d710^\u221210"
            },
            "measures": "[log ratio, activation z-score, overlap P-value]",
            "outcomes": "[2.152, 4.395, 5.12\u00d710^\u221210]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "STAT1",
                "activation z-score": "4.576",
                "overlap P-value": "2.05\u00d710^\u221208"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[4.576, 2.05\u00d710^\u221208]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "ETS1",
                "log ratio": "0.863",
                "activation z-score": "2.575",
                "overlap P-value": "5.06\u00d710^\u221208"
            },
            "measures": "[log ratio, activation z-score, overlap P-value]",
            "outcomes": "[0.863, 2.575, 5.06\u00d710^\u221208]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "JUN",
                "activation z-score": "2.045",
                "overlap P-value": "5.57\u00d710^\u221208"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[2.045, 5.57\u00d710^\u221208]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "FOXO1",
                "activation z-score": "3.242",
                "overlap P-value": "9.35\u00d710^\u221208"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[3.242, 9.35\u00d710^\u221208]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "E2F3",
                "log ratio": "1.137",
                "activation z-score": "2.394",
                "overlap P-value": "1.16\u00d710^\u221206"
            },
            "measures": "[log ratio, activation z-score, overlap P-value]",
            "outcomes": "[1.137, 2.394, 1.16\u00d710^\u221206]"
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "regulation type": "activation",
                "transcription regulator": "MBD2",
                "activation z-score": "2.549",
                "overlap P-value": "5.41\u00d710^\u221206"
            },
            "measures": "[activation z-score, overlap P-value]",
            "outcomes": "[2.549, 5.41\u00d710^\u221206]"
        }
    ],
    "PMC3428781_1": [
        {
            "subject": {
                "phenotype": "quiescent PSCs",
                "characteristic": "Vitamin A lipid droplets",
                "state": "present"
            }
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "Vitamin A lipid droplets",
                "state": "absent"
            }
        },
        {
            "subject": {
                "phenotype": "quiescent PSCs",
                "characteristic": "\u03b1 Smooth muscle actin",
                "state": "absent"
            }
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "\u03b1 Smooth muscle actin",
                "state": "present"
            }
        },
        {
            "subject": {
                "phenotype": "quiescent PSCs",
                "characteristic": "proliferation",
                "state": "limited"
            }
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "proliferation",
                "state": "increased"
            }
        },
        {
            "subject": {
                "phenotype": "quiescent PSCs",
                "characteristic": "migration",
                "state": "limited"
            }
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "migration",
                "state": "increased"
            }
        },
        {
            "subject": {
                "phenotype": "quiescent PSCs",
                "characteristic": "extracellular matrix production",
                "state": "limited"
            }
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "extracellular matrix production",
                "state": "increased"
            }
        },
        {
            "subject": {
                "phenotype": "quiescent PSCs",
                "characteristic": "matrix metalloproteinases (MMPs) and tissue inhibitors of matrix proteinases (TIMPs)",
                "state": "complement of MMPs and TIMPs to maintain normal ECM turnover"
            }
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "matrix metalloproteinases (MMPs) and tissue inhibitors of matrix proteinases (TIMPs)",
                "state": "change in types of MMPs and TIMPs to facilitate ECM deposition"
            }
        },
        {
            "subject": {
                "phenotype": "quiescent PSCs",
                "characteristic": "production of cytokines",
                "state": "limited"
            }
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "production of cytokines",
                "state": "increased (PDGF, TGF\u03b2, CTGF, IL1, IL6, IL15)"
            }
        },
        {
            "subject": {
                "phenotype": "quiescent PSCs",
                "characteristic": "capacity for phagocytosis",
                "state": "absent"
            }
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "capacity for phagocytosis",
                "state": "present"
            }
        },
        {
            "subject": {
                "phenotype": "quiescent PSCs",
                "characteristic": "proteomic analyses",
                "state": "basal protein expression"
            }
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "proteomic analyses",
                "state": "differential expression of proteins related to the cell cytoskeleton, cell metabolism, motility, growth and invasion"
            }
        }
    ],
    "PMC4941331_3": [
        {
            "subject": {
                "analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                "group": "Cytoplasmic CDH1 Low",
                "nuclear HDAC3 expression": "Low",
                "tumor tissue sample count": "34",
                "correlation coefficient": "0.440",
                "P-value": "< 0.001"
            },
            "measures": "[Spearman correlation coefficient]",
            "outcomes": "[0.440]"
        },
        {
            "subject": {
                "analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                "group": "Cytoplasmic CDH1 Low",
                "nuclear HDAC3 expression": "High",
                "tumor tissue sample count": "22",
                "correlation coefficient": "0.440",
                "P-value": "< 0.001"
            },
            "measures": "[Spearman correlation coefficient]",
            "outcomes": "[0.440]"
        },
        {
            "subject": {
                "analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                "group": "Cytoplasmic CDH1 High",
                "nuclear HDAC3 expression": "Low",
                "tumor tissue sample count": "4",
                "correlation coefficient": "0.440",
                "P-value": "< 0.001"
            },
            "measures": "[Spearman correlation coefficient]",
            "outcomes": "[0.440]"
        },
        {
            "subject": {
                "analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                "group": "Cytoplasmic CDH1 High",
                "nuclear HDAC3 expression": "High",
                "tumor tissue sample count": "24",
                "correlation coefficient": "0.440",
                "P-value": "< 0.001"
            },
            "measures": "[Spearman correlation coefficient]",
            "outcomes": "[0.440]"
        }
    ],
    "PMC6062623_3": [
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Right",
                "density threshold": "0.1"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.76, 0.002]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Right",
                "density threshold": "0.15"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.15, 0.008]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Right",
                "density threshold": "0.2"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.25, 0.006]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Right",
                "density threshold": "0.25"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.08, 0.009]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Left",
                "density threshold": "0.1"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-1.04, 0.32]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Left",
                "density threshold": "0.15"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-2.58, 0.022]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Left",
                "density threshold": "0.2"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.36, 0.005]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Left",
                "density threshold": "0.25"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.04, 0.01]"
        }
    ],
    "PMC5464866_2": [
        {
            "subject": {
                "analysis": "FXR expression in the cancerous tissues and the adjacent tissues",
                "group": "Cancerous tissues",
                "comparison to": "Adjacent tissues",
                "expression level": "protein level",
                "method": "immunohistochemistry",
                "patients": "88",
                "FXR positive": "54 (61.4%)",
                "FXR negative": "34 (38.6%)",
                "statistical significance": "P < 0.05"
            },
            "measures": "[metric, outcome]",
            "outcomes": ""
        },
        {
            "subject": {
                "analysis": "FXR expression in the cancerous tissues and the adjacent tissues",
                "group": "Adjacent tissues",
                "comparison to": "Cancerous tissues",
                "expression level": "protein level",
                "method": "immunohistochemistry",
                "patients": "88",
                "FXR positive": "27 (30.7%)",
                "FXR negative": "61 (69.3%)",
                "statistical significance": "P < 0.05"
            },
            "measures": "[metric, outcome]",
            "outcomes": ""
        }
    ],
    "PMC5687650_6": [
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Gender (Women or Men)",
                "type of analysis": "Univariate",
                "OR (95% CI)": "0.770 (0.528-1.124)",
                "P value": "0.175"
            },
            "measures": "[OR (95% CI), P]",
            "outcomes": "[0.770 (0.528-1.124), 0.175]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Gender (Women or Men)",
                "type of analysis": "Multivariate",
                "OR (95% CI)": "-",
                "P value": "-"
            }
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Age (>65 years or \u226465 years)",
                "type of analysis": "Univariate",
                "OR (95% CI)": "0.773 (0.537-1.110)",
                "P value": "0.163"
            },
            "measures": "[OR (95% CI), P]",
            "outcomes": "[0.773 (0.537-1.110), 0.163]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Age (>65 years or \u226465 years)",
                "type of analysis": "Multivariate",
                "OR (95% CI)": "-",
                "P value": "-"
            }
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "PLR (high or low)",
                "type of analysis": "Univariate",
                "OR (95% CI)": "0.922 (0.641-1.325)",
                "P value": "0.660"
            },
            "measures": "[OR (95% CI), P]",
            "outcomes": "[0.922 (0.641-1.325), 0.660]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "PLR (high or low)",
                "type of analysis": "Multivariate",
                "OR (95% CI)": "-",
                "P value": "-"
            }
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "NLR (high or low)",
                "type of analysis": "Univariate",
                "OR (95% CI)": "1.007 (0.701-1.448)",
                "P value": "0.969"
            },
            "measures": "[OR (95% CI), P]",
            "outcomes": "[1.007 (0.701-1.448), 0.969]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "NLR (high or low)",
                "type of analysis": "Multivariate",
                "OR (95% CI)": "-",
                "P value": "-"
            }
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Post/pre-chemotherapy PLR ratio (>1 or \u22641)",
                "type of analysis": "Univariate",
                "OR (95% CI)": "1.272 (0.881-1.837)",
                "P value": "0.199"
            },
            "measures": "[OR (95% CI), P]",
            "outcomes": "[1.272 (0.881-1.837), 0.199]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Post/pre-chemotherapy PLR ratio (>1 or \u22641)",
                "type of analysis": "Multivariate",
                "OR (95% CI)": "-",
                "P value": "-"
            }
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Post/pre-chemotherapy NLR ratio (>1 or \u22641)",
                "type of analysis": "Univariate",
                "OR (95% CI)": "1.902 (1.290-2.803)",
                "P value": "0.001**"
            },
            "measures": "[OR (95% CI), P]",
            "outcomes": "[1.902 (1.290-2.803), 0.001**]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Post/pre-chemotherapy NLR ratio (>1 or \u22641)",
                "type of analysis": "Multivariate",
                "OR (95% CI)": "1.902 (1.290-2.803)",
                "P value": "0.001**"
            },
            "measures": "[OR (95% CI), P]",
            "outcomes": "[1.902 (1.290-2.803), 0.001**]"
        }
    ],
    "PMC5464866_1": [
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "Low FXR expression",
                "timepoint": "0 year",
                "statistical representation": "percentage"
            },
            "measures": "[number at risk]",
            "outcomes": "[87(49.7%)]"
        },
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "Low FXR expression",
                "timepoint": "2 year",
                "statistical representation": "percentage"
            },
            "measures": "[number at risk]",
            "outcomes": "[16(9.1%)]"
        },
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "Low FXR expression",
                "timepoint": "4 year",
                "statistical representation": "percentage"
            },
            "measures": "[number at risk]",
            "outcomes": "[6(3.4%)]"
        },
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "Low FXR expression",
                "timepoint": "6 year",
                "statistical representation": "percentage"
            },
            "measures": "[number at risk]",
            "outcomes": "[1(0.6%)]"
        },
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "High FXR expression",
                "timepoint": "0 year",
                "statistical representation": "percentage"
            },
            "measures": "[number at risk]",
            "outcomes": "[88(50.3%)]"
        },
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "High FXR expression",
                "timepoint": "2 year",
                "statistical representation": "percentage"
            },
            "measures": "[number at risk]",
            "outcomes": "[9(5.1%)]"
        },
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "High FXR expression",
                "timepoint": "4 year",
                "statistical representation": "percentage"
            },
            "measures": "[number at risk]",
            "outcomes": "[3(1.7%)]"
        },
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "High FXR expression",
                "timepoint": "6 year",
                "statistical representation": "percentage"
            },
            "measures": "[number at risk]",
            "outcomes": "[0(0.0%)]"
        },
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "Low FXR expression"
            },
            "measures": "[median survival time (year)]",
            "outcomes": "[1.83]"
        },
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "High FXR expression"
            },
            "measures": "[median survival time (year)]",
            "outcomes": "[1.78]"
        },
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "Low FXR expression",
                "timepoint": "3 year",
                "statistical representation": "95% CI"
            },
            "measures": "[survival rate]",
            "outcomes": "[0.4288(0.3020~0.6089)]"
        },
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "Low FXR expression",
                "timepoint": "5 year",
                "statistical representation": "95% CI"
            },
            "measures": "[survival rate]",
            "outcomes": "[0.3127(0.1776~0.5503)]"
        },
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "High FXR expression",
                "timepoint": "3 year",
                "statistical representation": "95% CI"
            },
            "measures": "[survival rate]",
            "outcomes": "[0.3036(0.1646~0.5600)]"
        },
        {
            "subject": {
                "analysis": "detailed survival data of pancreatic cancer based on FXR expression",
                "group": "High FXR expression",
                "timepoint": "5 year",
                "statistical representation": "95% CI"
            },
            "measures": "[survival rate]",
            "outcomes": "[0.2277(0.0989~0.5241)]"
        }
    ],
    "PMC5641200_3": [
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Red blood cells count decreased",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G1"
            },
            "measures": "[n (%)]",
            "outcomes": "[5 (83)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Red blood cells count decreased",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G2"
            },
            "measures": "[n (%)]",
            "outcomes": "[1 (17)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Red blood cells count decreased",
                "dose level": "Level 2",
                "number of patients": "4",
                "grade": "G1"
            },
            "measures": "[n (%)]",
            "outcomes": "[2 (50)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Leukopenia",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G1"
            },
            "measures": "[n (%)]",
            "outcomes": "[3 (50)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Leukopenia",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G2"
            },
            "measures": "[n (%)]",
            "outcomes": "[1 (17)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Leukopenia",
                "dose level": "Level 2",
                "number of patients": "4",
                "grade": "G1"
            },
            "measures": "[n (%)]",
            "outcomes": "[2 (50)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Leukopenia",
                "dose level": "Level 2",
                "number of patients": "4",
                "grade": "G2"
            },
            "measures": "[n (%)]",
            "outcomes": "[1 (25)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Neutropenia",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G1"
            },
            "measures": "[n (%)]",
            "outcomes": "[4 (67)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Neutropenia",
                "dose level": "Level 2",
                "number of patients": "4",
                "grade": "G1"
            },
            "measures": "[n (%)]",
            "outcomes": "[1 (25)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Neutropenia",
                "dose level": "Level 2",
                "number of patients": "4",
                "grade": "G2"
            },
            "measures": "[n (%)]",
            "outcomes": "[1 (25)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "AST increase",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G1"
            },
            "measures": "[n (%)]",
            "outcomes": "[3 (50)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "AST increase",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G3"
            },
            "measures": "[n (%)]",
            "outcomes": "[1 (17)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "AST increase",
                "dose level": "Level 2",
                "number of patients": "4",
                "grade": "G1"
            },
            "measures": "[n (%)]",
            "outcomes": "[4 (100)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "ALT increase",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G1"
            },
            "measures": "[n (%)]",
            "outcomes": "[4 (67)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "ALT increase",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G2"
            },
            "measures": "[n (%)]",
            "outcomes": "[1 (17)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "ALT increase",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G3"
            },
            "measures": "[n (%)]",
            "outcomes": "[1 (17)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "ALT increase",
                "dose level": "Level 2",
                "number of patients": "4",
                "grade": "G1"
            },
            "measures": "[n (%)]",
            "outcomes": "[3 (75)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "GGT increase",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G1"
            },
            "measures": "[n (%)]",
            "outcomes": "[1 (17)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "GGT increase",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G2"
            },
            "measures": "[n (%)]",
            "outcomes": "[1 (17)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Hypocalcemia",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G1"
            },
            "measures": "[n (%)]",
            "outcomes": "[1 (17)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Hypocalcemia",
                "dose level": "Level 1",
                "number of patients": "6",
                "grade": "G2"
            },
            "measures": "[n (%)]",
            "outcomes": "[2 (33)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Hypocalcemia",
                "dose level": "Level 2",
                "number of patients": "4",
                "grade": "G1"
            },
            "measures": "[n (%)]",
            "outcomes": "[1 (25)]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "criteria": "NCI-CTCAE v4.03",
                "adverse event": "Hypocalcemia",
                "dose level": "Level 2",
                "number of patients": "4",
                "grade": "G2"
            },
            "measures": "[n (%)]",
            "outcomes": "[1 (25)]"
        }
    ],
    "PMC5716794_2": [
        {
            "subject": {
                "analysis": "ROC analyses of the different ROIs derived mean ADCs",
                "diagnosis": "differential diagnosis of mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC)",
                "ROI size (mm\u00b2)": "55",
                "optimal cutoff value (\u00d7 10\u207b\u00b3 mm\u00b2/s)": "1.70",
                "AUC \u00b1 SE (95% CI)": "0.687 \u00b1 0.079 (0.575\u22120.785)",
                "sensitivity (95% CI)": "89.1 (78.8 \u221295.5)",
                "specificity (95% CI)": "50.0 (26.0 \u221274.0)",
                "PPV (%)": "86.4",
                "NPV (%)": "56.3",
                "ACC (%)": "80.5"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
        },
        {
            "subject": {
                "analysis": "ROC analyses of the different ROIs derived mean ADCs",
                "diagnosis": "differential diagnosis of mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC)",
                "ROI size (mm\u00b2)": "82",
                "optimal cutoff value (\u00d7 10\u207b\u00b3 mm\u00b2/s)": "1.72",
                "AUC \u00b1 SE (95% CI)": "0.694 \u00b1 0.077 (0.582\u22120.791)",
                "sensitivity (95% CI)": "90.6 (80.7 \u221296.5)",
                "specificity (95% CI)": "50.0 (26.0 \u221274.0)",
                "PPV (%)": "86.6",
                "NPV (%)": "59.9",
                "ACC (%)": "81.7"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
        },
        {
            "subject": {
                "analysis": "ROC analyses of the different ROIs derived mean ADCs",
                "diagnosis": "differential diagnosis of mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC)",
                "ROI size (mm\u00b2)": "99",
                "optimal cutoff value (\u00d7 10\u207b\u00b3 mm\u00b2/s)": "1.73",
                "AUC \u00b1 SE (95% CI)": "0.707 \u00b1 0.074 (0.596\u22120.802)",
                "sensitivity (95% CI)": "90.6 (80.7 \u221296.5)",
                "specificity (95% CI)": "50.0 (26.0 \u221274.0)",
                "PPV (%)": "86.6",
                "NPV (%)": "59.9",
                "ACC (%)": "81.7"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
        },
        {
            "subject": {
                "analysis": "ROC analyses of the different ROIs derived mean ADCs",
                "diagnosis": "differential diagnosis of mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC)",
                "ROI size (mm\u00b2)": "134",
                "optimal cutoff value (\u00d7 10\u207b\u00b3 mm\u00b2/s)": "1.74",
                "AUC \u00b1 SE (95% CI)": "0.731 \u00b1 0.070 (0.622\u22120.823)",
                "sensitivity (95% CI)": "90.6 (80.7 \u221296.5)",
                "specificity (95% CI)": "50.0 (26.0 \u221274.0)",
                "PPV (%)": "86.6",
                "NPV (%)": "59.9",
                "ACC (%)": "81.7"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
        },
        {
            "subject": {
                "analysis": "ROC analyses of the different ROIs derived mean ADCs",
                "diagnosis": "differential diagnosis of mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC)",
                "ROI size (mm\u00b2)": "152",
                "optimal cutoff value (\u00d7 10\u207b\u00b3 mm\u00b2/s)": "1.70",
                "AUC \u00b1 SE (95% CI)": "0.751 \u00b1 0.067 (0.643\u22120.840)",
                "sensitivity (95% CI)": "89.1 (78.8 \u221295.5)",
                "specificity (95% CI)": "55.6 (30.8 \u221278.5)",
                "PPV (%)": "87.7",
                "NPV (%)": "58.9",
                "ACC (%)": "81.7"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
        },
        {
            "subject": {
                "analysis": "ROC analyses of the different ROIs derived mean ADCs",
                "diagnosis": "differential diagnosis of mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC)",
                "ROI size (mm\u00b2)": "161",
                "optimal cutoff value (\u00d7 10\u207b\u00b3 mm\u00b2/s)": "1.70",
                "AUC \u00b1 SE (95% CI)": "0.756 \u00b1 0.065 (0.649\u22120.844)",
                "sensitivity (95% CI)": "89.1 (78.8 \u221295.5)",
                "specificity (95% CI)": "55.6 (30.8 \u221278.5)",
                "PPV (%)": "87.7",
                "NPV (%)": "58.9",
                "ACC (%)": "81.7"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
        },
        {
            "subject": {
                "analysis": "ROC analyses of the different ROIs derived mean ADCs",
                "diagnosis": "differential diagnosis of mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC)",
                "ROI size (mm\u00b2)": "189",
                "optimal cutoff value (\u00d7 10\u207b\u00b3 mm\u00b2/s)": "1.75",
                "AUC \u00b1 SE (95% CI)": "0.770 \u00b1 0.062 (0.664\u22120.856)",
                "sensitivity (95% CI)": "90.6 (80.7 \u221296.5)",
                "specificity (95% CI)": "55.6 (30.8 \u221278.5)",
                "PPV (%)": "87.9",
                "NPV (%)": "62.5",
                "ACC (%)": "82.9"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
        },
        {
            "subject": {
                "analysis": "ROC analyses of the different ROIs derived mean ADCs",
                "diagnosis": "differential diagnosis of mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC)",
                "ROI size (mm\u00b2)": "214",
                "optimal cutoff value (\u00d7 10\u207b\u00b3 mm\u00b2/s)": "1.79",
                "AUC \u00b1 SE (95% CI)": "0.788 \u00b1 0.059 (0.684\u22120.871)",
                "sensitivity (95% CI)": "92.2 (82.7 \u221297.4)",
                "specificity (95% CI)": "55.6 (30.8 \u221278.5)",
                "PPV (%)": "88.1",
                "NPV (%)": "66.7",
                "ACC (%)": "84.2"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
        },
        {
            "subject": {
                "analysis": "ROC analyses of the different ROIs derived mean ADCs",
                "diagnosis": "differential diagnosis of mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC)",
                "ROI size (mm\u00b2)": "223",
                "optimal cutoff value (\u00d7 10\u207b\u00b3 mm\u00b2/s)": "1.79",
                "AUC \u00b1 SE (95% CI)": "0.793 \u00b1 0.058 (0.689\u22120.874)",
                "sensitivity (95% CI)": "93.8 (84.8 \u221298.3)",
                "specificity (95% CI)": "55.6 (30.8 \u221278.5)",
                "PPV (%)": "88.3",
                "NPV (%)": "71.6",
                "ACC (%)": "85.4"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
        },
        {
            "subject": {
                "analysis": "ROC analyses of the different ROIs derived mean ADCs",
                "diagnosis": "differential diagnosis of mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC)",
                "ROI size (mm\u00b2)": "245",
                "optimal cutoff value (\u00d7 10\u207b\u00b3 mm\u00b2/s)": "1.79",
                "AUC \u00b1 SE (95% CI)": "0.800 \u00b1 0.056 (0.697\u22120.881)",
                "sensitivity (95% CI)": "95.3 (86.9 \u221299.0)",
                "specificity (95% CI)": "55.6 (30.8 \u221278.5)",
                "PPV (%)": "88.4",
                "NPV (%)": "76.9",
                "ACC (%)": "86.6"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
        }
    ],
    "PMC3757392_2": [
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "C595:MUC1",
                "cell line": "Capan-1",
                "ICC (immunocytochemistry)": "++",
                "flow cytometry": "40",
                "confocal microscopy": "++",
                "Do (kBq)": "170"
            },
            "measures": "[flow cytometry, confocal microscopy, Do (kBq)]",
            "outcomes": "[40, ++, 170]"
        },
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "C595:MUC1",
                "cell line": "Cfpac-1",
                "ICC (immunocytochemistry)": "+++",
                "flow cytometry": "500",
                "confocal microscopy": "+++",
                "Do (kBq)": "140"
            },
            "measures": "[flow cytometry, confocal microscopy, Do (kBq)]",
            "outcomes": "[500, +++, 140]"
        },
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "C595:MUC1",
                "cell line": "Panc-1",
                "ICC (immunocytochemistry)": "+++",
                "flow cytometry": "80",
                "confocal microscopy": "+++",
                "Do (kBq)": "160"
            },
            "measures": "[flow cytometry, confocal microscopy, Do (kBq)]",
            "outcomes": "[80, +++, 160]"
        },
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "394:uPA",
                "cell line": "Capan-1",
                "ICC (immunocytochemistry)": "++",
                "flow cytometry": "88",
                "confocal microscopy": "++",
                "Do (kBq)": "190"
            },
            "measures": "[flow cytometry, confocal microscopy, Do (kBq)]",
            "outcomes": "[88, ++, 190]"
        },
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "394:uPA",
                "cell line": "Cfpac-1",
                "ICC (immunocytochemistry)": "+++",
                "flow cytometry": "92",
                "confocal microscopy": "+++",
                "Do (kBq)": "130"
            },
            "measures": "[flow cytometry, confocal microscopy, Do (kBq)]",
            "outcomes": "[92, +++, 130]"
        },
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "394:uPA",
                "cell line": "Panc-1",
                "ICC (immunocytochemistry)": "+++",
                "flow cytometry": "91",
                "confocal microscopy": "+++",
                "Do (kBq)": "170"
            },
            "measures": "[flow cytometry, confocal microscopy, Do (kBq)]",
            "outcomes": "[91, +++, 170]"
        },
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "2200-2500",
                "cell line": "all cells",
                "Do (kBq)": "2200-2500"
            },
            "measures": "[Do (kBq)]",
            "outcomes": "[2200-2500]"
        }
    ]
}